Published online Mar 7, 2023. doi: 10.3748/wjg.v29.i9.1460
Peer-review started: October 15, 2022
First decision: January 3, 2023
Revised: January 12, 2023
Accepted: February 27, 2023
Article in press: February 27, 2023
Published online: March 7, 2023
Processing time: 143 Days and 2.2 Hours
Viscoelastic tests, specifically thromboelastography and rotational thromboelastometry, are increasingly being used in the management of postoperative bleeding in surgical intensive care units (ICUs). However, life-threatening bleeds may complicate the clinical course of many patients admitted to medical ICUs, especially those with underlying liver dysfunction. Patients with cirrhosis have multiple coagulation abnormalities that can lead to bleeding or thrombotic complications. Compared to conventional coagulation tests, a comprehensive depiction of the coagulation process and point-of-care availability are advantages favoring these devices, which may aid physicians in making a rapid diagnosis and instituting early interventions. These tests may help predict bleeding and rationalize the use of blood products in these patients.
Core Tip: Viscoelastic hemostatic assays are increasingly used as “point-of-care” tests, providing real-time, dynamic insight into the complex coagulation aberrations seen in cirrhotic patients. In cirrhosis, all patients undergoing a high-risk invasive procedure or who are actively bleeding should undergo thromboelastography (TEG) on initial evaluation, if this testing is available. Any reasonable TEG-based strategy will likely represent an improvement over strategies using traditional coagulation tests. The best approach will be to use TEG supplemented by standard platelet count and fibrinogen testing. TEG is a promising diagnostic modality and may help in predicting bleeding and aid in the rationalization of the use of blood products in these patients.